A novel intravesical gene therapy for bladder cancer has shown such promising results in clinical trials that experts are suggesting that it be considered the "new gold standard," even though it is ...

Novel intravesical gene therapy given once every three months studied in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer Phase 3 clinical trial met its primary endpoint ...

The FDA has approved nadofaragene firadenovec (Adstiladrin) as the first gene therapy for the treatment of high-risk bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer ...

Q: In two weeks, I am supposed to get Botox injections in my bladder for an overactive bladder (OAB) and my frequent need to urinate at nighttime. Are these injections safe? Are there any bad side ...

NEW ORLEANS -- Add-On IL15RaFc superagonist N-803 (VesAnktiva) to Bacillus Calmette-Guérin (BCG) treatment led to "a clinically meaningful benefit" in BCG-unresponsive non-muscle invasive bladder ...

While potty training is probably a distant childhood memory, the panicked feeling of “I need to pee right now and I don’t know if I can make it to the bathroom in time” is something many adults still ...

Patients with a high-risk bladder cancer now have a new option to treat it. The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin, which is designed to work for ...

Every time Erin publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from Business ...

Dear D.J.: The initial treatment for OAB symptoms usually consists of lifestyle changes (i.e., quitting smoking, avoiding medications that worsen symptoms and excess fluid intake at night), pelvic ...

Adstiladrin represents the first gene therapy approved by the FDA for the treatment of patients with high-risk non-muscle invasive bladder cancer who are resistant to BCG, the first-line standard of ...

More than half the patients with high-grade bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) treated with nadofaragene firadenovec, an investigational intravesical ...